IDOGEN.ST
Idogen AB (publ) [IDOGEN.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IDOGEN.ST Stock Summary
In the News
IDOGEN.ST Financial details
Company Rating
-
Market Cap
12.79M
Income
-44.13M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
12 May 2022
P/E
-0.35
Forward P/E
-
PEG
0.05
P/S
-
P/B
5.69
P/C
-
P/FCF
-0.42
Quick Ratio
0.96
Current Ratio
1.66
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.6
EPS next Y
-
EPS next Q
-
EPS this Y
-62.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-59.61%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-643%
ROE
-464%
ROC
-16.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0152-0.548
52W High
-
52W Low
-
RSI
-
Rel Volume
0.23
Avg Volume
4.95M
Volume
1.13M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-1.63%
-
-
-
-
Beta
1.77611
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.1205
Change
-2.82%
Company Profile
- Volume Average 4.95M
- Market Capitalization 12.79M
- Employee 6
- CEO Dr. Christina Herder Ph.D.
- Headquarters Lund,SE
- IPO Date 2015-06-12
-
Website
https://www.idogen.com 
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases. The company was incorporated in 2008 and is headquartered in Lund, Sweden.
